Headquartered in San Mateo, CA Fiscal year ends December NASDAQ: SGMT sagimet.com
Sagimet Biosciences is a clinical-stage biopharmaceutical company developing oral and topical inhibitors of fatty acid synthase (FASN). FASN is a key regulator of the de novo lipogenesis pathway, which is overactive in acne and can drive excess sebum and inflammation.
Its lead candidate, denifanstat, is an oral, once-daily FASN inhibitor in the registrational U.S. AURORA Phase 3 trial for moderate to severe acne. The first patient was dosed in October 2026, and topline data are expected in 2H 2027. License partner Ascletis develops denifanstat as ASC40 in Greater China, where it met all primary and secondary endpoints in Phase 3 and its NDA was accepted by the NMPA in December 2025.
The pipeline also includes:
- TVB-3567, a follow-on FASN inhibitor that has completed Phase 1 dosing, with a Phase 2 acne trial planned by year-end 2026.
- A topical FASN inhibitor formulation for acne.
- Denifanstat for MASH, where it met primary endpoints in a Phase 2b trial and holds FDA Breakthrough Therapy designation. A denifanstat-resmetirom combination is being pursued, but further MASH work is contingent on non-dilutive funding.
- Exploration of FASN-dependent tumor types in oncology.
The company has no product revenue. It funds operations through equity financings, including a [USD:115000000] gross offering in October 2026. Updated
The wider loss is the cost of going pivotal: R&D jumped to $16.34 million as the first patient was dosed in the AURORA Phase 3 acne trial of denifanstat. Pro forma cash of about $355.8 million funds operations through mid-2029, covering the 2H 2027 topline readout and an NDA.
Penny stocks are a fascinating category of investment opportunities. While risky, these stocks allow you to invest in companies when they’re young and underdeveloped. So making the right penny stock picks can…
Sagimet Biosciences is a clinical-stage biopharmaceutical company developing oral and topical inhibitors of fatty acid synthase (FASN). FASN is a key regulator of the de novo lipogenesis pathway, which is overactive in acne and can drive excess sebum and inflammation.
The Wall Street consensus 12-month price target for SGMT is $27.91.
